Review
doi: 10.1038/nrc1821.
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Affiliations
- PMID: 16498445
- DOI: 10.1038/nrc1821
Item in Clipboard
Review
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Nat Rev Cancer.
2006 Mar.
Abstract
The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and that might serve as intervention points for anticancer drugs. However, there are many criteria to consider in validating MMPs as drug targets and for the development of MMP inhibitors. The inhibition of some MMPs could have pro-tumorigenic effects (making them anti-targets), counterbalancing the benefits of target inhibition. These effects might partially account for the failure of MMP inhibitors in clinical trials. What are the major challenges in MMP target validation and MMP-inhibitor-drug development?
Similar articles
-
[Expression of matrix metalloproteinases in patients with malignant tumors].Medicina (Kaunas). 2004;40(12):1143-50. Medicina (Kaunas). 2004. PMID: 15630339 Review. Lithuanian.
-
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.Science. 2002 Mar 29;295(5564):2387-92. doi: 10.1126/science.1067100. Science. 2002. PMID: 11923519 Review.
-
Matrix metalloproteinases. Novel targets for directed cancer therapy.Drugs Aging. 1997 Sep;11(3):229-44. doi: 10.2165/00002512-199711030-00006. Drugs Aging. 1997. PMID: 9303281 Review.
-
Matrix metalloproteinases and cancer - roles in threat and therapy.Asian Pac J Cancer Prev. 2014;15(3):1085-91. doi: 10.7314/apjcp.2014.15.3.1085. Asian Pac J Cancer Prev. 2014. PMID: 24606423 Review.
-
Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.J Pharm Pharmacol. 2014 Jul;66(7):895-902. doi: 10.1111/jphp.12218. Epub 2014 Feb 12. J Pharm Pharmacol. 2014. PMID: 24697787 Review.
Cited by
-
Control and inhibition analysis of complex formation processes.Theor Biol Med Model. 2012 Aug 3;9:33. doi: 10.1186/1742-4682-9-33. Theor Biol Med Model. 2012. PMID: 22863329 Free PMC article.
-
Role of matrix Metalloproteinases in pituitary adenoma invasion.Chin Neurosurg J. 2018 Feb 9;4:2. doi: 10.1186/s41016-017-0109-0. eCollection 2018. Chin Neurosurg J. 2018. PMID: 32922863 Free PMC article. Review.
-
Nuclear Factor Kappa B, Matrix Metalloproteinase-1, p53, and Ki-67 Expressions in the Primary Tumors and the Lymph Node Metastases of Colorectal Cancer Cases.Gastroenterol Res Pract. 2015;2015:945392. doi: 10.1155/2015/945392. Epub 2015 Apr 6. Gastroenterol Res Pract. 2015. PMID: 25945089 Free PMC article.
-
DIGRE: Drug-Induced Genomic Residual Effect Model for Successful Prediction of Multidrug Effects.CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e1. doi: 10.1002/psp4.1. Epub 2015 Feb 18. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26225227 Free PMC article.
-
Improving matrix metalloproteinase-2 specific response of a hydrogel system using electrophoresis.Int J Pharm. 2012 Jun 15;429(1-2):31-7. doi: 10.1016/j.ijpharm.2012.03.012. Epub 2012 Mar 13. Int J Pharm. 2012. PMID: 22440150 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
